| Everolimus Plus Best Supportive Care vs Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced Neuroendocrine Tumors (GI or Lung Origin) (NCT01524783) | Novartis Pharmaceuticals | 2012-03-30 |
| Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors (NCT01619865) | Sue O'Dorisio | 2012-02-21 |
| Preoperative Imaging in Patients With Small Bowel Neuroendocrine Tumors (NCT05246319) | Laurent BRUNAUD | 2012-01-01 |
| Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Metastases (NCT01469572) | Emory University | 2011-12-01 |
| Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas (NCT01744249) | Grupo Espanol de Tumores Neuroendocrinos | 2011-11-01 |
| A Multicenter Study Evaluating Efficacy and Safety of 177Lu-DOTA-TATE Based on Kidney-Dosimetry in Patients With Disseminated Neuroendocrine Tumors (NCT01456078) | Lund University Hospital | 2011-10-01 |
| Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs) (NCT01364415) | Novartis Pharmaceuticals | 2011-08-01 |
| Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. (NCT01398306) | University Medical Center Groningen | 2011-07-01 |
| Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors (NCT01970540) | PharmaMar | 2011-05-25 |
| An Open-label, Multi-center, Expanded Access Study of Everolimus in Participants With Advanced Neuroendocrine Tumors (NETs) (Core Study) and an Extension Study to the Open-label, Multi-center, Expanded Access Study of Everolimus in Patients With Advanced NETs (E1) (NCT01595009) | Novartis Pharmaceuticals | 2011-04-27 |
| RAD001 With Paclitaxel and Carboplatin in First Line Treatment of Patients With Advanced Large Cell Lung Cancer With Neuroendocrine Differentiation (NCT01317615) | Novartis Pharmaceuticals | 2011-04-01 |
| Measurement Variability of Liver Metastases From Neuroendocrine Tumors on Different Magnetic Resonance Imaging Sequences (NCT03948841) | CHU de Reims | 2011-01-01 |
| A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients (NCT01262235) | Arbutus Biopharma Corporation | 2010-12-01 |
| 177Lutetium-DOTA-Octreotate Therapy in Somatostatin Receptor-Expressing Neuroendocrine Neoplasms (NCT01237457) | Ebrahim S Delpassand | 2010-10-27 |
| A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea (NCT01234168) | Ipsen | 2010-10-01 |
| Study of Everolimus (RAD001) in Combination With Lenalidomide (NCT01218555) | Emory University | 2010-09-09 |
| Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies (NCT01163526) | Stanford University | 2010-09-01 |
| Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE) (NCT01201096) | University of Jena | 2010-09-01 |
| Safety and Tolerability Profile of RAD001 Daily in Chinese Patients With Advanced Pulmonary Neuroendocrine Tumor (NCT01175096) | Guangdong Provincial People's Hospital | 2010-07-01 |
| Study of Panobinostat in Patients With Neuroendocrine Tumors (NCT00985946) | University of Wisconsin, Madison | 2010-05-01 |
| Yttrium-90 Radioembolization Using Glass Microspheres (TheraSphere) for Patients With Liver Metastases (NCT01290536) | Nicholas Fidelman, MD | 2010-05-01 |
| 89Zr-bevacizumab PET Imaging in Patients With Neuroendocrine Tumors (NCT01338090) | University Medical Center Groningen | 2010-04-01 |
| Phase I Study of the Safety, Distribution, and Radiation Dosimetry of Ultratrace Iobenguane 123I-mIBG (NCT01730417) | Bennett Chin | 2009-11-01 |
| RAD001 and Erlotinib in Patients With Neuroendocrine Tumors (NCT00843531) | University of California, San Francisco | 2009-06-25 |
| Follow Up Protocol for Subjects Previously Enrolled on NCI Surgery Branch Studies (NCT00923026) | National Cancer Institute (NCI) | 2009-06-15 |
| ProGRP, CgA, NSE and TUM2-PK in in Patients With Neuroendocrine Tumors (NCT00851604) | Hadassah Medical Organization | 2009-03-01 |
| A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors (NCT00947167) | Pamela L. Kunz | 2009-03-01 |
| A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer (NCT00781911) | Eli Lilly and Company | 2009-02-01 |
| HRQoL During PRRT in Patients With NETs (NCT05427032) | Uppsala University | 2009-01-10 |
| Non Interventional Post Marketing Programme in Neuroendocrine Tumours (NCT00747786) | Ipsen | 2008-12-01 |
| B-Receptor Signaling in Cardiomyopathy (NCT01135849) | Daniel Bernstein | 2008-11-01 |
| Best Therapy for Patients With Neuroendocrine Tumors (NCT00815620) | Zentralklinik Bad Berka | 2008-11-01 |
| Predictive Biomarkers of Response to Sunitinib in the Treatment of Poorly-differentiated NEURO-Endocrine Tumors (NCT01215578) | Assistance Publique - Hôpitaux de Paris | 2008-10-01 |
| Quarfloxin in Patients With Low to Intermediate Grade Neuroendocrine Carcinoma (NCT00780663) | Cylene Pharmaceuticals | 2008-10-01 |
| 11C-Acetate PET/CT Non-FDG-Avid Tumors (NCT00687778) | Tel-Aviv Sourasky Medical Center | 2008-05-01 |
| Ki67 Proliferation Index of Pancreatic Neuroendocrine Neoplasia (NCT04753229) | Institut Paoli-Calmettes | 2008-01-01 |
| Clinical and Translational Study of MK-0646 in Patients With Metastatic Neuroendocrine Tumors (NET) (NCT00610129) | Memorial Sloan Kettering Cancer Center | 2008-01-01 |
| SwissNET - a Registry for Neuroendocrine Tumours in Switzerland (NCT01039922) | Insel Gruppe AG, University Hospital Bern | 2008-01-01 |
| Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors (NCT00605566) | University Health Network, Toronto | 2008-01-01 |
| Lithium for Low-Grade Neuroendocrine Tumors (NCT00501540) | University of Wisconsin, Madison | 2007-07-01 |
| Clinical and Pathologic Studies in Neuroendocrine Tumors (NCT00657332) | Stanford University | 2007-07-01 |
| Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors (NCT00398320) | Pamela L. Kunz | 2006-11-01 |
| Combination Targeted Radiotherapy in Neuroendocrine Tumors (NCT01099228) | David Bushnell | 2006-09-01 |
| Pemetrexed in Patients With Advanced Neuroendocrine Tumors (NCT00424723) | Dana-Farber Cancer Institute | 2005-12-01 |
| Capecitabine and Temozolomide for Neuroendocrine Cancers (NCT00869050) | Columbia University | 2005-08-01 |
| Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors (NCT00442533) | Radio Isotope Therapy of America | 2005-08-01 |
| Effect of Oral 5-HTP Intake on Urinary 5-HIAA Excretion (NCT00227136) | University of Western Ontario, Canada | 2005-05-01 |
| Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression (NCT04029428) | University of Warmia and Mazury | 2004-11-02 |
| Bevacizumab in Combination With Temozolomide in Patients With Neuroendocrine Tumors (NCT00137774) | Dana-Farber Cancer Institute | 2004-11-01 |
| Imaging of Neuroendocrine Tumors With PET and Fluoro-18-DOPA (F-DOPA) (NCT02539433) | Northwell Health | 2003-12-01 |
| Treatment With SU11248 in Patients With Neuroendocrine Tumors (NCT00056693) | Pfizer | 2003-04-01 |
| EPO906 in Carcinoid and Other Neuroendocrine Tumors (NCT00050349) | Novartis Pharmaceuticals | 2002-07-01 |
| 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors (NCT00953394) | University of Turin, Italy | 2002-02-01 |
| High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors (NCT00037869) | M.D. Anderson Cancer Center | 2001-11-01 |
| Antiproliferative Effect of Octreotide in Patients With Metastasized Neuroendocrine Tumors of the Midgut (NCT00171873) | Carmen Schade-Brittinger | 2001-09-01 |
| Prophylactic Cholecystectomy is Not Mandatory in Patients Candidate to the Resection for Small Intestine Neuroendocrine Neoplasms: a Propensity Score-matched and Cost-minimization Analysis (NCT04780737) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2000-01-01 |
| DOTA-TOC in Metastasized Neuroendocrine Tumors (NCT00978211) | University Hospital, Basel, Switzerland | 1997-09-01 |
| 68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial (NCT02358018) | Memorial Sloan Kettering Cancer Center | |
| Copper Cu 64 Dotatate for the Detection, Localization and Monitoring of SSTR Expressing (NETs) (NCT04334837) | Curium US LLC | |
| EAP 177Lu-DOTA0-Tyr3-Octreotate for Inoperable, SSR+, NETs, Progressive Under SSA Tx (NCT02705313) | Advanced Accelerator Applications | |
| Expanded Access Program of Surufatinib (NCT04814732) | Hutchmed | |
| 68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access) (NCT02174679) | Jonsson Comprehensive Cancer Center | |